Oppenheimer & CO Inc Uni Qure N.V. Transaction History

Oppenheimer & CO Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 24, 2019	SELL	$27.39 - $68.41 $198,550 - $495,904	-7,249 Closed	0 $0
Q4 2018 Jan 29, 2019	SELL	$22.8 - $33.93 $9,712 - $14,454	-426 Reduced 5.55%	7,249 $209,000
Q3 2018 Oct 26, 2018	BUY	$29.75 - $43.08 $228,331 - $330,639	7,675 New	7,675 $279,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.